Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Pegylated Liposomal Irinotecan

A formulation of polyethylene glycol (PEG)-modified liposomes encapsulating the semisynthetic derivative of camptothecin irinotecan, with… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication… Expand
Is this relevant?
2017
2017
Opsonization (coating) of nanoparticles with complement C3 component is an important mechanism that triggers immune clearance and… Expand
Is this relevant?
Review
2017
Review
2017
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Shire Pharmaceuticals) of pegylated… Expand
Is this relevant?
2015
2015
IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11). The objective of this study was to evaluate the factors… Expand
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • table 2
Is this relevant?
2012
2012
PurposeIHL-305 is a novel PEGylated liposome containing irinotecan. This study examined the safety profile and pharmacokinetics… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
2012
2012
Medullary thyroid carcinoma is a rare endocrine tumor, which shows overexpression of somatostatin receptor subtype 2. There is no… Expand
Is this relevant?
2011
2011
OBJECTIVES Liposomal delivery of irinotecan could provide protection against drug hydrolysis, deliver more active lactone form to… Expand
Is this relevant?
2009
2009
2547 Background: Irinotecan (CPT-11) is a prodrug of SN-38 that has antitumor activity in a wide range of solid tumors. IHL- 305… Expand
Is this relevant?